[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][Branch2][Ring2][C][C][C@@H1][Ring1][Ring1][C][=Branch1][C][=O][N][/C][=Branch1][P][=C][\\C][C][C][C][S][C][C@@H1][Branch1][=Branch1][C][=Branch1][C][=O][O][N][/C][=Branch1][C][=O][O][C]"}, {"from": "gpt", "value": "The molecule is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism. The first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam]."}]